Literature DB >> 7059436

Isoniazid disposition, comparison of isoniazid phenotyping methods in and acetylator distribution of Japanese patients with idiopathic systemic lupus erythematosus and control subjects.

Y Horai, T Ishizaki, T Sasaki, G Koya, K Matsuyama, S Iguchi.   

Abstract

1 Plasma levels of isoniazid (INH) and acetyl INH in plasma were measured with a spectrofluorometric method, and INH and its metabolites (acetyl INH, mono-acetylhydrazine, diacetylhydrazine and free hydrazine) excreted in urine were measured with a gas chromatography-mass spectrometry, respectively, after an oral dose of INH 10 mg/kg in 19 Japanese patients with idiopathic systemic lupus erythematosus (SLE) and in the same number of healthy controls. 2 When phenotyped according to various methods previously reported, 16 to 18 of the SLE and 17 to 19 of the control group were rapid acetylators. Regardless of the phenotyping methods applied, the distribution of acetylator phenotype of SLE patients was not significantly different from the control group or from the data previously reported among normal Japanese population. 3 By phenotyping our subjects with an INH T 1/2 of 110 min or less as rapid acetylators, and more slow acetylators, 3 of SLE patients and 2 of the controls were slow, while the remainder were all rapid. When this antimode was used, the mean apparent kinetic variables of INH and acetyl INH estimated from the plasma concentration-time data and the mean values for the 24-h urinary amount of INH and its metabolites, except for monoacetylhydrazine (P less than 0.05), did not significantly differ between the rapid acetylators of SLE and control groups. 4 The distribution of INH T 1/2, acetyl INH to INH ratios in plasma and urine, values in urine for log10 (diacetylhydrazine to monoacetylhydrazine) and for diacetylhydrazine to INH or acetyl INH was similar between the two groups except for one patient who was definitely classified as a slow acetylator regardless of whichever phenotyping methods were used. The excretory patterns of hydrazine compounds reflect, in general, the inactivating ability of INH in each individual. 5 The data suggest that phenotyping by using plasma samples is, in general, better than by using urine samples. The plasma T 1/2 alone is the most satisfactory criterion. 6 We conclude that neither INH disposition nor phenotype distribution assessed by the reported methods using INH as the test compound are altered in idiopathic SLE, and that a search for racial and/or geographical factor(s) likely to result in autoimmune disease may give a clue to the pathogenesis in addition to further exploration for the possible interrelation between idiopathic SLE and genetic slow acetylation.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7059436      PMCID: PMC1402126          DOI: 10.1111/j.1365-2125.1982.tb01387.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  44 in total

Review 1.  The epidemiology of systemic lupus erythematosus.

Authors:  M Siegel; S L Lee
Journal:  Semin Arthritis Rheum       Date:  1973       Impact factor: 5.532

2.  Isoniazid inactivation in Finns and Lapps as demonstrated by various methods.

Authors:  H Tittinen; M J Mattila; A W Eriksson
Journal:  Am Rev Respir Dis       Date:  1973-08

3.  Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine.

Authors:  H M Perry; E M Tan; S Carmody; A Sakamoto
Journal:  J Lab Clin Med       Date:  1970-07

4.  Determination of the acetylator phenotype from the ratio of the urinary excretion of acetylisoniazid to acid-labile isoniazid: a study in Finnish Lapland.

Authors:  G A Ellard; P T Gammon; H Tiitinen
Journal:  Tubercle       Date:  1973-09

5.  Classification of subjects as slow or rapid inactivators of isoniazid, based on the ratio of the urinary excretion of acetylisoniazid to isoniazid.

Authors:  P Venkataraman; N K Menon; N G Nair; S Radhakrishna; C Ross; S P Tripathy
Journal:  Tubercle       Date:  1972-06

6.  Inactivation of isoniazid (INH) in Swedish tuberculous patients before and during treatment with para-aminosalicylic acid (PAS).

Authors:  A Hanngren; O Borgå; F Sjöqvist
Journal:  Scand J Respir Dis       Date:  1970

7.  The discrimination of phenotypes for rate of disappearance of isonicotinoyl hydrazide from serum.

Authors:  E M Scott; R C Wright; D D Weaver
Journal:  J Clin Invest       Date:  1969-07       Impact factor: 14.808

8.  Isoniazid and ethionamide serum levels and inactivation in Finnish subjects.

Authors:  H Tiitinen
Journal:  Scand J Respir Dis       Date:  1969

9.  The polymorphic acetylation of dapsone in man.

Authors:  R Gelber; J H Peters; G R Gordon; A J Glazko; L Levy
Journal:  Clin Pharmacol Ther       Date:  1971 Mar-Apr       Impact factor: 6.875

10.  The acetylator phenotype of patients with systemic lupus erythematosus.

Authors:  M M Reidenberg; J H Martin
Journal:  Drug Metab Dispos       Date:  1974 Jan-Feb       Impact factor: 3.922

View more
  9 in total

1.  Genetically determined N-acetylation and oxidation capacities in Japanese patients with non-occupational urinary bladder cancer.

Authors:  Y Horai; K Fujita; T Ishizaki
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 2.  Survey of the human acetylator polymorphism in spontaneous disorders.

Authors:  D A Evans
Journal:  J Med Genet       Date:  1984-08       Impact factor: 6.318

3.  N-acetylation phenotyping with dapsone in a mainland Chinese population.

Authors:  Y Horai; H H Zhou; L M Zhang; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

4.  Acetylation polymorphism and leprosy.

Authors:  L C Eze; A N Okpogba; A U Ogan
Journal:  Biochem Genet       Date:  1990-02       Impact factor: 1.890

Review 5.  Genetically determined variability in acetylation and oxidation. Therapeutic implications.

Authors:  D W Clark
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

6.  Hydralazine-induced lupus: is there a toxic metabolic pathway?

Authors:  J A Timbrell; V Facchini; S J Harland; R Mansilla-Tinoco
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

7.  N-acetylation polymorphism of dapsone in a Japanese population.

Authors:  Y Horai; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1988-04       Impact factor: 4.335

Review 8.  Clinical pharmacokinetics of the antituberculosis drugs.

Authors:  M R Holdiness
Journal:  Clin Pharmacokinet       Date:  1984 Nov-Dec       Impact factor: 6.447

9.  Population Pharmacokinetics and Pharmacodynamics of Isoniazid and its Metabolite Acetylisoniazid in Chinese Population.

Authors:  Bing Chen; Hao-Qiang Shi; Meihua Rose Feng; Xi-Han Wang; Xiao-Mei Cao; Wei-Min Cai
Journal:  Front Pharmacol       Date:  2022-07-19       Impact factor: 5.988

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.